Identifying new ways to predict tuberculosis treatment outcomes
C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB Study
This study is looking for better ways to check if tuberculosis treatments have worked by examining certain markers in patients after they finish their treatment, so we can help teenagers and adults avoid relapsing in the future.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11090185 on NIH RePORTER |
What this research studies
This research investigates innovative methods to assess the effectiveness of tuberculosis (TB) treatments by analyzing biomarkers in patients at the end of their treatment. Current methods, like sputum cultures, are slow and often unreliable in predicting relapse. By focusing on new non-culture assays, the study aims to find more accurate predictors of microbiologic relapse in adolescents and adults who have completed standard TB treatment. The research is part of a larger network aimed at improving diagnostic tools for TB.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents and adults who have recently completed treatment for drug-susceptible pulmonary tuberculosis.
Not a fit: Patients with drug-resistant forms of tuberculosis or those who have not undergone the standard 4-drug regimen may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more effective treatments for tuberculosis, reducing the risk of relapse.
How similar studies have performed: Previous research has shown promise in using novel biomarkers to predict treatment outcomes in tuberculosis, suggesting that this approach could be effective.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Nahid, Payam — University of California, San Francisco
- Study coordinator: Nahid, Payam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.